Mixed connective tissue disease, a roundabout to rheumatic diseases?

Silvia Bellando-Randone, Maurizio Cutolo, L. Czirják, Marco Matucci-Cerinic

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Mixed Connective Tissue Disease (MCTD) has originally been described as a syndrome that consisted of a combination of features typically found in patients with Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), or rheumatoid arthritis (RA). Objective: The diagnosis of MCTD still remains controversial and it is critically dependent on the demonstration of high-titer anti-U1-RNP antibodies. When first described, MCTD, was believed to have a good prognosis. After longer follow-up studies this opinion has now been revisited: the prognosis in MCTD is in fact worse than that in LES, most of the deaths being due to pulmonary hypertension. The main question is whether or not MCTD patients have a distinctive clinical course, prognosis and treatment requirements. Conclusion: The importance of MCTD is not much in terms of diagnosis, but rather what antibody tells us about patients. The clinician must anticipate by treating the potential lethal complication of pulmonary hypertension, myositis and fibrosing alveolitis, and the tendency of the disease to evolve into one of its sister disease.

Original languageEnglish
Pages (from-to)133-140
Number of pages8
JournalCurrent Rheumatology Reviews
Volume5
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Mixed Connective Tissue Disease
Rheumatic Diseases
Pulmonary Hypertension
Myositis
Dermatomyositis
Antibodies
Pulmonary Fibrosis
Systemic Scleroderma
Systemic Lupus Erythematosus
Siblings
Rheumatoid Arthritis

Keywords

  • Capillaroscopy
  • MCTD
  • Systemic sclerosis
  • Therapy

ASJC Scopus subject areas

  • Rheumatology

Cite this

Mixed connective tissue disease, a roundabout to rheumatic diseases? / Bellando-Randone, Silvia; Cutolo, Maurizio; Czirják, L.; Matucci-Cerinic, Marco.

In: Current Rheumatology Reviews, Vol. 5, No. 2, 2009, p. 133-140.

Research output: Contribution to journalArticle

Bellando-Randone, Silvia ; Cutolo, Maurizio ; Czirják, L. ; Matucci-Cerinic, Marco. / Mixed connective tissue disease, a roundabout to rheumatic diseases?. In: Current Rheumatology Reviews. 2009 ; Vol. 5, No. 2. pp. 133-140.
@article{8ddfe0d463104af8806da5e1e8e44565,
title = "Mixed connective tissue disease, a roundabout to rheumatic diseases?",
abstract = "Introduction: Mixed Connective Tissue Disease (MCTD) has originally been described as a syndrome that consisted of a combination of features typically found in patients with Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), or rheumatoid arthritis (RA). Objective: The diagnosis of MCTD still remains controversial and it is critically dependent on the demonstration of high-titer anti-U1-RNP antibodies. When first described, MCTD, was believed to have a good prognosis. After longer follow-up studies this opinion has now been revisited: the prognosis in MCTD is in fact worse than that in LES, most of the deaths being due to pulmonary hypertension. The main question is whether or not MCTD patients have a distinctive clinical course, prognosis and treatment requirements. Conclusion: The importance of MCTD is not much in terms of diagnosis, but rather what antibody tells us about patients. The clinician must anticipate by treating the potential lethal complication of pulmonary hypertension, myositis and fibrosing alveolitis, and the tendency of the disease to evolve into one of its sister disease.",
keywords = "Capillaroscopy, MCTD, Systemic sclerosis, Therapy",
author = "Silvia Bellando-Randone and Maurizio Cutolo and L. Czirj{\'a}k and Marco Matucci-Cerinic",
year = "2009",
doi = "10.2174/157339709788298437",
language = "English",
volume = "5",
pages = "133--140",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Mixed connective tissue disease, a roundabout to rheumatic diseases?

AU - Bellando-Randone, Silvia

AU - Cutolo, Maurizio

AU - Czirják, L.

AU - Matucci-Cerinic, Marco

PY - 2009

Y1 - 2009

N2 - Introduction: Mixed Connective Tissue Disease (MCTD) has originally been described as a syndrome that consisted of a combination of features typically found in patients with Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), or rheumatoid arthritis (RA). Objective: The diagnosis of MCTD still remains controversial and it is critically dependent on the demonstration of high-titer anti-U1-RNP antibodies. When first described, MCTD, was believed to have a good prognosis. After longer follow-up studies this opinion has now been revisited: the prognosis in MCTD is in fact worse than that in LES, most of the deaths being due to pulmonary hypertension. The main question is whether or not MCTD patients have a distinctive clinical course, prognosis and treatment requirements. Conclusion: The importance of MCTD is not much in terms of diagnosis, but rather what antibody tells us about patients. The clinician must anticipate by treating the potential lethal complication of pulmonary hypertension, myositis and fibrosing alveolitis, and the tendency of the disease to evolve into one of its sister disease.

AB - Introduction: Mixed Connective Tissue Disease (MCTD) has originally been described as a syndrome that consisted of a combination of features typically found in patients with Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), or rheumatoid arthritis (RA). Objective: The diagnosis of MCTD still remains controversial and it is critically dependent on the demonstration of high-titer anti-U1-RNP antibodies. When first described, MCTD, was believed to have a good prognosis. After longer follow-up studies this opinion has now been revisited: the prognosis in MCTD is in fact worse than that in LES, most of the deaths being due to pulmonary hypertension. The main question is whether or not MCTD patients have a distinctive clinical course, prognosis and treatment requirements. Conclusion: The importance of MCTD is not much in terms of diagnosis, but rather what antibody tells us about patients. The clinician must anticipate by treating the potential lethal complication of pulmonary hypertension, myositis and fibrosing alveolitis, and the tendency of the disease to evolve into one of its sister disease.

KW - Capillaroscopy

KW - MCTD

KW - Systemic sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=71849118980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849118980&partnerID=8YFLogxK

U2 - 10.2174/157339709788298437

DO - 10.2174/157339709788298437

M3 - Article

AN - SCOPUS:71849118980

VL - 5

SP - 133

EP - 140

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 2

ER -